ES492664A0 - A PROCEDURE FOR THE PREPARATION OF A MURAMILDIPEPTIDE. - Google Patents

A PROCEDURE FOR THE PREPARATION OF A MURAMILDIPEPTIDE.

Info

Publication number
ES492664A0
ES492664A0 ES492664A ES492664A ES492664A0 ES 492664 A0 ES492664 A0 ES 492664A0 ES 492664 A ES492664 A ES 492664A ES 492664 A ES492664 A ES 492664A ES 492664 A0 ES492664 A0 ES 492664A0
Authority
ES
Spain
Prior art keywords
group
carbon atoms
image
acyl
muramildipeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES492664A
Other languages
Spanish (es)
Other versions
ES8200645A1 (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Pharmaceutical Co Ltd
Original Assignee
Daiichi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Pharmaceutical Co Ltd filed Critical Daiichi Pharmaceutical Co Ltd
Publication of ES492664A0 publication Critical patent/ES492664A0/en
Publication of ES8200645A1 publication Critical patent/ES8200645A1/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
    • C07K9/005—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure containing within the molecule the substructure with m, n > 0 and m+n > 0, A, B, D, E being heteroatoms; X being a bond or a chain, e.g. muramylpeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Muramyldipeptide derivatives of the formula (I): <IMAGE> (I) wherein X represents an amino acid residue such as of L-alanine, L-serine, L-valine, glycine, etc., and Y represents a group <IMAGE> wherein R1 represents a hydrogen atom, an alkyl group of 1 to 6 carbon atoms, a carboxamide group or a carboxyl group, n represents an integer of 1 to 6, A represents a straight or branched chain, saturated or unsaturated aliphatic hydrocarbon residue of 7 to 30 carbon atoms, and "Acyl" means an acyl group of an aliphatic carboxylic acid having 2 to 6 carbon atoms. These compounds have excellent adjuvant activity and/or prophylactic and therapeutic effects against microbial infections.
ES492664A 1979-06-21 1980-06-20 Muramyldipeptide derivatives, process for preparing said compounds and pharmaceutical compositions containing said compounds. Expired ES8200645A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP7831779A JPS5618996A (en) 1979-06-21 1979-06-21 Muramyldipeptide derivative

Publications (2)

Publication Number Publication Date
ES492664A0 true ES492664A0 (en) 1981-11-16
ES8200645A1 ES8200645A1 (en) 1981-11-16

Family

ID=13658554

Family Applications (1)

Application Number Title Priority Date Filing Date
ES492664A Expired ES8200645A1 (en) 1979-06-21 1980-06-20 Muramyldipeptide derivatives, process for preparing said compounds and pharmaceutical compositions containing said compounds.

Country Status (11)

Country Link
US (1) US4317771A (en)
EP (1) EP0021367B1 (en)
JP (1) JPS5618996A (en)
AT (1) ATE2958T1 (en)
AU (1) AU534233B2 (en)
CA (1) CA1183128A (en)
DE (1) DE3062609D1 (en)
ES (1) ES8200645A1 (en)
PH (1) PH15892A (en)
SU (1) SU1190990A3 (en)
ZA (1) ZA803483B (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2482959A2 (en) * 1979-06-29 1981-11-27 Rhone Poulenc Ind Merrifield synthesis of immunostimulant and adjuvant tri:peptide(s) - produces fatty acid acrylated l-alanine d-glutamic acid 2-lysine or 2,6-di:amino-pimelamic acid cpds.
GR78246B (en) * 1981-01-23 1984-09-26 Ciba Geigy Ag
US4522811A (en) * 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
JPS5920297A (en) * 1982-07-27 1984-02-01 Dai Ichi Seiyaku Co Ltd Muramyldipeptide derivative
JPS59172497A (en) * 1983-03-22 1984-09-29 Dai Ichi Seiyaku Co Ltd Novel muramyl peptide derivative
FR2546756B1 (en) * 1983-06-03 1985-11-29 Centre Nat Rech Scient NOVEL IMMUNOSTIMULATING DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION AS MEDICAMENTS
US4474693A (en) * 1983-10-31 1984-10-02 E. R. Squibb & Sons, Inc. ACE inhibitors produced from Nocardia orientalis
JPS6157597A (en) * 1984-08-29 1986-03-24 Toshiyuki Hamaoka Active ester derivative of muramyl peptide
JPS6393724A (en) * 1986-10-09 1988-04-25 Dai Ichi Seiyaku Co Ltd Analgesic and anti-inflammatory agent containing muramyl dipeptide derivative
US5416070A (en) * 1988-07-08 1995-05-16 Immunotherapeutics, Inc. Composition for macrophage activation
US4950645A (en) * 1988-07-08 1990-08-21 Immunotherapeutics, Inc. Composition for macrophage activation
GB9320820D0 (en) * 1993-10-08 1993-12-01 Biokine Tech Ltd Compounds for medicinal use
CN100522995C (en) * 2003-10-22 2009-08-05 中国医学科学院药物研究所 Cell wall acyl-alanyl-D-isoglutamine derivative and its preparation, medicine composition and use
US9688718B2 (en) 2008-01-11 2017-06-27 Lawrence Livermore National Security, Llc Nanolipoprotein particles comprising hydrogenases and related products, methods and systems
US9303273B2 (en) 2008-05-09 2016-04-05 Lawrence Livermore National Security, Llc Nanolipoprotein particles comprising a natural rubber biosynthetic enzyme complex and related products, methods and systems
WO2009143280A2 (en) * 2008-05-22 2009-11-26 Lawrence Livermore National Security, Llc Nanolipoprotein particles and related compositions, methods and systems
JP5922104B2 (en) 2010-05-27 2016-05-24 シェンヅェン サルブリス ファーマシューティカルズ カンパニー リミテッドＳｈｅｎｚｈｅｎ Ｓａｌｕｂｒｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏ．， Ｌｔｄ Chemical synthesis and anti-tumor and anti-tumor metastatic effects of dual functional conjugates
CN102219834A (en) * 2011-04-14 2011-10-19 北京市丰硕维康技术开发有限责任公司 Method for preparing romurtide
US9644038B2 (en) 2011-12-21 2017-05-09 The Regents Of The University Of California Apolipoprotein nanodiscs with telodendrimer
WO2016049061A1 (en) 2014-09-22 2016-03-31 Lawrence Livermore National Security, Llc Electrochemical flow-cell for hydrogen production and nicotinamide co-factor dependent target reduction, and related methods and systems
US10610564B2 (en) 2015-02-26 2020-04-07 Stc.Unm IRGM and precision autophagy controls for antimicrobial and inflammatory disease states and methods of detection of autophagy
US11279749B2 (en) 2015-09-11 2022-03-22 Lawrence Livermore National Security, Llc Synthetic apolipoproteins, and related compositions methods and systems for nanolipoprotein particles formation
US12083223B2 (en) 2017-05-02 2024-09-10 Lawrence Livermore National Security, Llc Nanolipoprotein particles and related compositions methods and systems for loading RNA
WO2018204421A2 (en) 2017-05-02 2018-11-08 Lawrence Livermore National Security, Llc Momp telonanoparticles, and related compositions, methods and systems
MX2023011004A (en) 2021-03-19 2024-01-08 Trained Therapeutix Discovery Inc Compounds for regulating trained immunity, and their methods of use.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH613709A5 (en) * 1975-12-10 1979-10-15 Ciba Geigy Ag Process for the preparation of glucosamine derivatives
FR2358159A1 (en) * 1976-07-16 1978-02-10 Anvar 2- (2-ACETAMIDO-2-DEOXY-3 - O-D-GLUCOPYRANOSYL) - D-PROPIONYL-L-ALANYL-D-GLUTAMIC ACID DIAMIDE AND DRUGS CONTAINING IT
FI66878C (en) * 1978-02-24 1984-12-10 Ciba Geigy Ag FOERFARANDE FOER FRAMSTAELLNING AV NYA ANTIGENDERIVAT
FR2442241A2 (en) * 1978-03-20 1980-06-20 Anvar NOVEL ESTER COMPOUNDS OF MURAMYL-PEPTIDE, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, IN PARTICULAR IN THE FORM OF LIPOSOMES
FR2428050A1 (en) * 1978-06-05 1980-01-04 Anvar OLIGOMERS OF MURAMYL-PEPTIDE COMPOUNDS AND DRUGS CONTAINING THEM
US4256735A (en) * 1979-01-29 1981-03-17 Merck & Co., Inc. Immunologically active dipeptidyl saccharides and methods of preparation

Also Published As

Publication number Publication date
PH15892A (en) 1983-04-14
AU534233B2 (en) 1984-01-12
SU1190990A3 (en) 1985-11-07
DE3062609D1 (en) 1983-05-11
CA1183128A (en) 1985-02-26
EP0021367A1 (en) 1981-01-07
ATE2958T1 (en) 1983-04-15
ZA803483B (en) 1981-06-24
AU5910180A (en) 1981-01-08
JPS6227079B2 (en) 1987-06-12
US4317771A (en) 1982-03-02
EP0021367B1 (en) 1983-04-06
JPS5618996A (en) 1981-02-23
ES8200645A1 (en) 1981-11-16

Similar Documents

Publication Publication Date Title
ES492664A0 (en) A PROCEDURE FOR THE PREPARATION OF A MURAMILDIPEPTIDE.
DK116480A (en) PROCEDURE FOR PREPARING SUBSTITUTED CHROMONS
ES2140717T3 (en) SUBSTITUTED 3-ARYLIDENO-7-AZAOXYDOLES COMPOUNDS AND THEIR PREPARATION PROCEDURE.
DE3270583D1 (en) Inhibitors of mammalian collagenase
IE801251L (en) Inhibitors of mammalian collagenase
SE9100342D0 (en) NOVEL STEROID ESTERS
ES488788A0 (en) PROCEDURE FOR PREPARING A PARTICULAR PHARMACEUTICAL COMPOSITION IN PSYCHOTROP.
SE8604950D0 (en) DEMENTIA IMPROVING AND THERAPEUTIC AGENTS
ES493302A0 (en) PROCEDURE FOR THE PREPARATION OF BIS-AMIDES OF 5-AMINO-2,4,6-TRIYODO-ISOPHTHALIC ACIDS
ES505672A0 (en) PROCEDURE FOR THE PREPARATION OF OXIMES OF PYRUTICAL ACIDS
ES2076623T3 (en) 3,4-DIHIDRO-NAFTALINAS SUBSTITUTED, ITS PREPARATION PROCEDURE AND MEDICINES THAT CONTAIN THEM.
RS50423B (en) Novel octahydro-6,10-dioxo-6h-pyridazino(1,2-a)diazepin -1-carboxylic acid derivatives, preparation method and use for preparing therapeutically active compounds
SE8206981D0 (en) N- (VINBLASTINOYL-23) DERIVATIVES OF AMINO ACIDS, THEIR PREPARATION AND THERAPEUTICAL APPLICATION
GEP19970937B (en) Method of producing derivatives of muramyldipeptide
EP0331756A4 (en) Agents for prophylaxis and treatment of thrombopenia
ES453997A1 (en) Secondary etheramine acetates and their use as lubricating agents for synthetic fibers
DK128892A (en) BENZYLETHER DERIVATIVES
ES465567A1 (en) 2-amino-cyclopent-1-ene-1-thiocarboxylic acid-disulphides and a process for the preparation thereof
SE7714525L (en) METHODS OF PRODUCING N-SUBSTITUTED 2-AMINOCYCLOPENT-1-EN-1-DITIOCARBOXYLIC ACIDS

Legal Events

Date Code Title Description
PC1A Transfer granted